Centene (NYSE:CNC) PT Lowered to $67.00 at Mizuho

Centene (NYSE:CNC) had its price target lowered by equities researchers at Mizuho from $75.00 to $67.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage currently has a “neutral” rating on the stock. Mizuho’s price objective suggests a potential upside of 5.03% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley reduced their target price on Centene from $94.00 to $88.00 and set an “overweight” rating on the stock in a report on Tuesday, August 31st. Stephens upgraded Centene from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $71.00 to $87.00 in a report on Tuesday, May 11th. Truist Securities lifted their price objective on Centene from $80.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, June 17th. Bank of America lifted their price objective on Centene from $75.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, June 8th. Finally, Roth Capital began coverage on Centene in a report on Tuesday, August 17th. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $81.97.

Shares of CNC opened at $63.79 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.63. Centene has a 1 year low of $53.60 and a 1 year high of $75.59. The stock has a market cap of $37.19 billion, a P/E ratio of 52.29, a price-to-earnings-growth ratio of 1.09 and a beta of 0.46. The stock’s 50-day moving average price is $68.46 and its two-hundred day moving average price is $67.17.

(Ad)

Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.

Centene (NYSE:CNC) last issued its earnings results on Monday, July 26th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.41 by ($0.16). Centene had a return on equity of 10.39% and a net margin of 0.61%. The company had revenue of $31.03 billion for the quarter, compared to the consensus estimate of $30.11 billion. During the same quarter last year, the business posted $2.40 EPS. Centene’s quarterly revenue was up 12.0% on a year-over-year basis. As a group, equities analysts forecast that Centene will post 5.14 EPS for the current year.

In other news, Director Orlando Ayala sold 9,366 shares of Centene stock in a transaction that occurred on Thursday, July 29th. The stock was sold at an average price of $70.00, for a total transaction of $655,620.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Brent D. Layton sold 4,000 shares of Centene stock in a transaction that occurred on Thursday, July 29th. The stock was sold at an average price of $70.00, for a total value of $280,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 68,366 shares of company stock worth $4,785,170 in the last ninety days. Insiders own 1.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Argent Trust Co boosted its stake in Centene by 1.1% in the 2nd quarter. Argent Trust Co now owns 14,729 shares of the company’s stock valued at $1,074,000 after purchasing an additional 158 shares during the period. Checchi Capital Advisers LLC lifted its position in shares of Centene by 4.0% during the 1st quarter. Checchi Capital Advisers LLC now owns 4,617 shares of the company’s stock valued at $295,000 after acquiring an additional 177 shares during the period. Duncker Streett & Co. Inc. lifted its position in shares of Centene by 2.9% during the 2nd quarter. Duncker Streett & Co. Inc. now owns 6,455 shares of the company’s stock valued at $471,000 after acquiring an additional 183 shares during the period. Rikoon Group LLC lifted its position in shares of Centene by 2.0% during the 1st quarter. Rikoon Group LLC now owns 9,577 shares of the company’s stock valued at $612,000 after acquiring an additional 186 shares during the period. Finally, High Pointe Capital Management LLC lifted its position in shares of Centene by 2.2% during the 1st quarter. High Pointe Capital Management LLC now owns 8,990 shares of the company’s stock valued at $575,000 after acquiring an additional 190 shares during the period. Institutional investors and hedge funds own 91.75% of the company’s stock.

About Centene

Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid.

Featured Story: Debt-To-Equity Ratio

The Fly logo

Analyst Recommendations for Centene (NYSE:CNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Centene right now?

Before you consider Centene, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Centene wasn’t on the list.

While Centene currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

.